Ovarian Serous Adenocarcinoma

This case underscores the diagnostic challenges of MLA, particularly its ability to masquerade as low-grade or high-grade serous carcinoma on morphology, including cytology, frozen, and permanent sections. We compare the cytologic, histologic, immunophenotypic, and molecular features of MLA and serous carcinoma, highlighting the importance of thorough evaluation to avoid the pitfall of morphology-only diagnosis.

P=N/A, N=1330, Completed, Abramson Cancer Center at Penn Medicine | Enrolling by invitation --> Completed | N=3000 --> 1330

Moreover, SOD2 expression correlated with signatures related to pro-tumorigenic neutrophil and T-regulatory cell populations. Our data suggest SOD2 positively regulates pro-metastatic pathways, and those identified in MCAs more closely reflect gene expression profiles associated with SOD2 expression in patient tumors.

Moreover, HDGF re-expression counteracted the suppressive effects of MAZ knockdown on HGSOC cell malignant behaviors, HUVEC tube formation, M2 macrophage polarization, and the growth of xenograft tumors. In conclusion, our study unveils the MAZ/HDGF axis as a novel SE-mediated oncogenic pathway in HGSOC, providing previously unrecognized insights into SE-driven oncogenesis and highlighting potential targets for HGSOC treatment.

IGF2BP3 knock down, and chemical blockade of de novo cholesterol biosynthesis, both alone or in combination, achieved attenuated disease progression, in vivo. Effectively, our study links RNA modifications with metabolic reprogramming in the HGSC mesenchymal subtype through delineation of a m6A-IGF2BP3-cholesterol biosynthesis axis-mediated regulation of tumor cell stemness and aggression.

This study proposes a panel of potential prognostic biomarkers for the treatment of ovarian cancer patients, particularly by leveraging TGFB2-dependent mRNA expression as a significant biomarker, alongside four additional TGFB2-independent prognostic markers, for patients undergoing Taxol-based therapies. Future prospective clinical trials will be required to validate these prognostic markers.

Elevated preoperative CA-125 levels are associated with advanced-stage and high-grade serous carcinomas. Moreover, higher-grade serous ovarian carcinomas are significantly associated with the presence of p53 mutations, providing valuable insights into pathogenesis and potential treatment strategies.

sCTCs revealed persistent CNAs in the CDK4 and emerging ones in the ALK oncogene. Notably, primary tumors revealed considerable fractions of shared genomic aberrations.

Dexamethasone 40 mg/day for four days restored counts. One year post-surgery, she remains without recurrent thrombocytopenia or disease progression. This pattern supports an immune mechanism and underscores the need for steroid therapy and withdrawal.

Increased PARPi sensitivity following ALC1 loss can be accurately predicted by endogenous single-stranded DNA levels, identifying a functional biomarker. Together, our studies define the clinical contexts in which the therapeutic utility of PARPi can be expanded by targeting ALC1, whose inhibitors are currently under evaluation in Phase I clinical trials.

FOLR1 is overexpressed in a large percentage of low-grade serous ovarian cancers. Mirvetuximab soravtansine may represent a novel treatment option for low-grade serous ovarian cancer patients progressing after standard treatment modalities. Clinical trials with mirvetuximab soravtansine in FOLR1-positive low-grade serous ovarian cancers are warranted.

P2, N=16, Active, not recruiting, Verastem, Inc. | Recruiting --> Active, not recruiting